Condition: End Stage Liver Disease · Sponsor: LyGenesis, Inc.
This Phase 2a clinical trial is a dose escalation study of the safety, tolerability, and efficacy of hepatocyte transplantation into lymph nodes via endoscopic ultrasound among subjects with end-stage liver disease.
This description comes directly from the study's public registry record.
Paulo Fontes, MD · 412-860-3599 · fontesp@lygenesis.com
Always discuss trial participation with your own doctor first.
| Tufts Medical Center | Boston, Massachusetts, United States | Withdrawn |
| Houston Methodist Hospital | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04496479